Click here for more information about how we are dealing with COVID-19 and what you should do for your visit.
Skip to main content


Brain imaging showing loss in serotonin function as Parkinson's disease progresses. Red/yellow areas show that serotonin func

Parkinson's Disease Clinical Trial

Parkinson's disease afflicts over one million people in the United States causing a decline in motor skills and cognition due to the destruction of dopamine producing neurons in the brain. Current research targets dopamine receptors in the brain.
Mar 8th, 2021

Alzheimer's Phase 2 Clinical Trial Success

Neurology Diagnostics is proud to announce our participation and enrollment of patients in the Eli Lilly Alzheimer's disease study recently reported in the New York Times.
Jan 20th, 2021
Neurology Diagnostics Digest

Neurology Diagnostics Digest - October 17, 2023

October 17, 2023 - Neurology Diagnostics’ Role in Advancing Alzheimer’s Research: LUCIDITY Phase 3 Outcomes - NDX Research Clinic Updates - New Referral Process - Accepting New Patients
Oct 17th, 2023
Neurology Diagnostics Digest

Neurology Diagnostics Digest - September 28, 2023

Neurology Diagnostics Newsletter Summary [date] Accepting new patients, streamlined referrals, FDA-approved Alzheimer's drug Leqembi, and upcoming clinical trials for Alzheimer's, CTE, and Parkinson's. Join us in advancing neurological care.
Sep 28th, 2023